PF-04455242

PF-04455242
Clinical data
Other namesPF-4455242; PF04455242; PF4455242
Routes of
administration		Oral[1]
Drug classκ-Opioid receptor antagonist
ATC code
  • None
Identifiers
  • 2-methyl-N-[[4-(2-pyrrolidin-1-ylsulfonylphenyl)phenyl]methyl]propan-1-amine
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC21H28N2O2S
Molar mass372.53 g·mol−1
3D model (JSmol)
  • CC(C)CNCC1=CC=C(C=C1)C2=CC=CC=C2S(=O)(=O)N3CCCC3
  • InChI=1S/C21H28N2O2S/c1-17(2)15-22-16-18-9-11-19(12-10-18)20-7-3-4-8-21(20)26(24,25)23-13-5-6-14-23/h3-4,7-12,17,22H,5-6,13-16H2,1-2H3
  • Key:OWVIKBRKPCTDEP-UHFFFAOYSA-N

PF-04455242 is an experimental κ-opioid receptor (KOR) antagonist which was under development by Pfizer for the treatment of bipolar depression but was never marketed.[1][2][3] Its development was discontinued in early clinical trials.[2][3] It is taken by mouth.[1]

  1. ^ a b c "PF 4455242". AdisInsight. Springer Nature Switzerland AG. 29 September 2010. Retrieved 28 September 2024.
  2. ^ a b Li W, Sun H, Chen H, Yang X, Xiao L, Liu R, et al. (2016). "Major Depressive Disorder and Kappa Opioid Receptor Antagonists". Translational Perioperative and Pain Medicine. 1 (2): 4–16. PMC 4871611. PMID 27213169.
  3. ^ a b Urbano M, Guerrero M, Rosen H, Roberts E (May 2014). "Antagonists of the kappa opioid receptor". Bioorganic & Medicinal Chemistry Letters. 24 (9): 2021–2032. doi:10.1016/j.bmcl.2014.03.040. PMID 24690494.